Karama Asleh
9PUBLICATIONS
30CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (9)
Sort by Publication Date:
|Nov 08, 2022
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine.Karama Asleh, Ana Lluch, Angela Goytain
|Sep 01, 2022
Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications.Karama Asleh, Nazia Riaz, Torsten O Nielsen
|Aug 12, 2022
Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial.Elahe Shenasa, Elisabeth Specht Stovgaard, Maj-Britt Jensen
|Feb 17, 2022
Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes.Karama Asleh, Gian Luca Negri, Sandra E Spencer Miko
|Oct 07, 2021
Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials.Karama Asleh, Dongsheng Tu, Dongxia Gao
|Sep 10, 2021
Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer.Karama Asleh, Nazia Riaz, Angela S Cheng
Pageof 2
Frequent Collaborators
3 joint publications
Torsten O Nielsen
2 joint publications
Samuel Leung
1 joint publications
Heikki Joensuu
1 joint publications
Nazia Riaz
1 joint publications
Dongsheng Tu
1 joint publications
Gian Luca Negri
1 joint publications
Sandra E Spencer Miko
1 joint publications
Christopher S Hughes
1 joint publications
Gregg B Morin
1 joint publications
Elahe Shenasa
